RiverFront Investment Group LLC Has $1.75 Million Stake in AbbVie Inc. $ABBV

RiverFront Investment Group LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,424 shares of the company’s stock after selling 490 shares during the period. RiverFront Investment Group LLC’s holdings in AbbVie were worth $1,749,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Nuveen LLC purchased a new position in AbbVie during the 1st quarter valued at about $1,819,154,000. Assenagon Asset Management S.A. grew its position in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after purchasing an additional 3,666,521 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in AbbVie by 31.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after buying an additional 3,519,187 shares during the period. Vanguard Group Inc. increased its stake in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in AbbVie in the 2nd quarter worth approximately $581,817,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ABBV. Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. Daiwa Capital Markets upgraded AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price on the stock in a research note on Thursday, August 7th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, UBS Group increased their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Stock Performance

Shares of ABBV opened at $229.61 on Tuesday. The company has a market capitalization of $405.81 billion, a PE ratio of 109.34, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company’s fifty day moving average price is $227.05 and its 200 day moving average price is $205.78.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.